Initiating or changing to a fixed-dose combination of fluticasone propionate/formoterol over fluticasone propionate/salmeterol : a real-life effectiveness and cost impact evaluation
| dc.contributor.author | Ming, Simon Wan Yau | |
| dc.contributor.author | Haughney, John | |
| dc.contributor.author | Small, Iain | |
| dc.contributor.author | Wolfe, Stephanie | |
| dc.contributor.author | Hamill, John | |
| dc.contributor.author | Gruffydd-Jones, Kevin | |
| dc.contributor.author | Daly, Cathal | |
| dc.contributor.author | Soriano, Joan B | |
| dc.contributor.author | Gardener, Elizabeth | |
| dc.contributor.author | Skinner, Derek | |
| dc.contributor.author | d'Alcontres, Martina Stagno | |
| dc.contributor.author | Price, David B. | |
| dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en |
| dc.contributor.institution | University of Aberdeen.Institute of Applied Health Sciences | en |
| dc.date.accessioned | 2018-06-24T23:03:01Z | |
| dc.date.available | 2018-06-24T23:03:01Z | |
| dc.date.embargoedUntil | 2018-06-24 | |
| dc.date.issued | 2017-08 | |
| dc.description | With institutional support from NAPP Pharmaceutical Group Ltd. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work and have given final approval to the version to be published. The authors would like to thank Rosalind Bonomally for medical writing support. | en |
| dc.description.status | Peer reviewed | en |
| dc.format.extent | 8 | |
| dc.format.extent | 142073 | |
| dc.identifier | 102432107 | |
| dc.identifier | 8b575593-422e-4871-a254-71623649e5d9 | |
| dc.identifier | 85021764258 | |
| dc.identifier.citation | Ming, S W Y, Haughney, J, Small, I, Wolfe, S, Hamill, J, Gruffydd-Jones, K, Daly, C, Soriano, J B, Gardener, E, Skinner, D, d'Alcontres, M S & Price, D B 2017, 'Initiating or changing to a fixed-dose combination of fluticasone propionate/formoterol over fluticasone propionate/salmeterol : a real-life effectiveness and cost impact evaluation', Respiratory Medicine, vol. 129, pp. 199-206. https://doi.org/10.1016/j.rmed.2017.06.016 | en |
| dc.identifier.doi | 10.1016/j.rmed.2017.06.016 | |
| dc.identifier.issn | 0954-6111 | |
| dc.identifier.uri | http://hdl.handle.net/2164/10654 | |
| dc.identifier.vol | 129 | en |
| dc.language.iso | eng | |
| dc.relation.ispartof | Respiratory Medicine | en |
| dc.subject | Asthma | en |
| dc.subject | Cost-effectiveness | en |
| dc.subject | Fixed-dose combination inhalers | en |
| dc.subject | Formoterol | en |
| dc.subject | GINA | en |
| dc.subject | Real-life | en |
| dc.subject | R Medicine (General) | en |
| dc.subject.lcc | R1 | en |
| dc.title | Initiating or changing to a fixed-dose combination of fluticasone propionate/formoterol over fluticasone propionate/salmeterol : a real-life effectiveness and cost impact evaluation | en |
| dc.type | Journal article | en |
